Citations

Clear

3485 citation(s) found for "Sy, Sarah".

A randomized phase II study of daratumumab, lenalidomide, ixazomib, and dexamethasone in transplant-ineligible or deferred patients with newly diagnosed multiple myeloma: Alliance Foundation Trial 41 (AFT-41)
Yee, Andrew, O'Donnell, Elizabeth, Nadeem, Omar, Nelson, Garth, Wildes, Tanya, Buck, Tondre, Tuchman, Sascha, Ghimire, Krishna, Sinclair, Sarah, Stewart, Catherine, Richardson, Paul, Usmani, Saad, Raje, Noopur, Yee, Andrew, O'Donnell, Elizabeth, Nadeem, Omar, Nelson, Garth, Wildes, Tanya, Buck, Tondre, Tuchman, Sascha, Ghimire, Krishna, Sinclair, Sarah, Stewart, Catherine, Richardson, Paul, Usmani, Saad, Raje, Noopur

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 4053-4053

10.1182/blood-2025-4053 Get It

Abstract Introduction The treatment of newly diagnosed multiple myeloma (NDMM) has rapidly evolved. Quadruplet induction combining an anti-CD38 monoclonal antibody, lenalidomide, a proteasome inhibitor, and dexamethasone has become a standard of care. In this prospective randomized phase 2 trial, we evaluated the efficacy and safety of induction with a four-drug combination of daratumumab (Dara), lenalidomide (R), ixazomib (I), and dexamethasone (d) (Dara-RId) in older, transplant ineligible or deferred patients, followed by maintenance with Dara RI versus R for up to 2 years. We hypothesized that this quadruplet would offer improved tolerability with less peripheral neuropathy in this older population as well as the convenience of largely oral therapy. Herein, we present the initial results of the induction phase of the study. Methods Transplant-ineligible or deferred patients with NDMM were eligible to participate. This was a multicenter trial sponsored by the Alliance Foundation Trials, LLC, AFT-41 (NCT04009109). Each cycle of treatment was 28 days. All patients received 12 cycles of induction therapy with daratumumab 1800 mg subcutaneously on the conventional schedule, lenalidomide 15 mg orally (po) on days 1-21, ixazomib 4 mg po on days 1, 8, 15, and dexamethasone weekly. After 12 cycles, patients received maintenance based on prior randomization (1:1) to Dara-RI or R for up to 2 years. In maintenance, R was reduced to 10 mg and I was reduced to 3 mg. Randomization assignment occurred prior to starting induction. Stratification was based on presence of high-risk features defined as ISS stage III or high-risk FISH cytogenetics (del 17, t (14;16), t (14;20), t (4;14), del (1p), or gain (1q)). The primary endpoint was progression-free survival (PFS). Secondary endpoints included objective response rate (ORR) and adverse events. Results We enrolled 79 patients across 7 sites from October 2020 until December 2023. Accrual was affected by the COVID19 pandemic, leading to early closure to accrual in December 2023. Median age was 74 years (range 63-86); ≥75 years of age (45.6%); female (59.5%); white (83.5%), African American (7.6%), Asian (1.3%), and Hispanic ethnicity (6.3%). Additional baseline characteristics included ISS staging I (41.8%), II (35.4%), and III (22.8%) with high-risk features in 37% by ISS stage III and/or high-risk FISH. The 12-month PFS was 92% (95% confidence interval [CI] 86.1-98.4%). The ORR (≥ partial response [PR]) during induction was 92.4% (PR 22.8%; very good partial response [VGPR] 46.8%; complete response 15.2%; stringent complete response 7.6%). Notable grade ≥3 adverse events included neutropenia (16.5%), infections (11.4%), anemia (10.1%), thrombocytopenia (8.9%), and syncope (7.6%). There was no grade ≥3 peripheral neuropathy (grade 1, 15%; grade 2, 14%). No treatment-related mortality was reported. Sixty-one patients went on to maintenance therapy and seven patients discontinued treatment for adverse events during induction (8.9%). Conclusions Dara-RId therapy in NDMM appears to be efficacious with an ORR of 92.4%; VGPR or better of 69.6% and 12-month PFS of 92%. The combination was generally tolerated well with manageable toxicity, despite 45.6% of patients being ≥75, offering the convenience of an oral proteasome inhibitor, ixazomib, that minimizes the risk of peripheral neuropathy for older, transplant-ineligible or deferred patients. Follow-up is ongoing to determine the benefit of maintenance with Dara-RI v. R alone in this population. Support: AFT, Celgene, Janssen, Takeda.
Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study
Cohen, Jonathon B. , Shah, Nirav N. , Ujjani, Chaitra S. , Kim, Won Seog , Alencar, Alvaro J. , Lewis, David , Woyach, Jennifer A. , Maddocks, Kami J. , Seymour, John F. , Nagai, Hirokazu, Vose, Julie, Fakhri, Bita , Hoffmann, Marc , Hernandez‐Ilizaliturri, Francisco J. , Kumar, Anita , Munir, Talha, Tsai, Donald E. , Abada, Paolo, Balbas, Minna, Eyre, Toby A. , Fakhri, Bita , Wang, Michael , Jurczak, Wojciech , Zinzani, Pier Luigi , Cheah, Chan Y. , Koh, Youngil , Nasta, Sunita , Flinn, Ian W. , Tessoulin, Benoit , Ma, Shuo , Patel, Krish , Wang, Yucai , Rhodes, Joanna , Tam, Constantine S. , Hoffmann, Marc, Zelenetz, Andrew D. , Li, Jian , Wang, Ying , Roeker, Lindsey E.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 665-665

10.1182/blood-2025-665 Get It

Abstract Background: Despite the efficacy of covalent Bruton tyrosine kinase inhibitors (cBTKi) in R/R MCL, patients (pts) ultimately discontinue treatment due to intolerance or development of resistance and disease relapse. Pirtobrutinib is a highly selective, non-covalent BTKi that inhibits BTK with low nM potency throughout the daily dosing interval. Pirtobrutinib was safe and effective in the phase 1/2 BRUIN study in pts with R/R B-cell malignancies, including those previously treated with a BTKi. Pirtobrutinib is approved in the EU for adults with R/R MCL after prior treatment with a BTKi (EMA Conditional Approval, Oct 2023), and in the USA for adults with R/R MCL after ≥ 2 lines of systemic therapy, including a BTKi (FDA Accelerated Approval, Jan 2023).Here, we report the final results from the phase 1/2 BRUIN study (NCT03740529), with a follow-up period of up to 5 yrs, focusing on the efficacy and safety of pirtobrutinib in all R/R MCL pts. Methods: Pts with R/R MCL who received ≥1 prior lines of therapy (including BTKi) were eligible for treatment with pirtobrutinib monotherapy. Key endpoints included overall response rate (ORR), duration of response (DOR) and progression-free survival (PFS), all assessed by independent review committee (IRC) per Lugano 2014 criteria (presented here) and investigator, overall survival (OS), and safety. Pts were included across the range of doses evaluated in dose escalation and expansion (25-300 mg/day). A data cutoff on 27 January 2025 was utilized, with a median study follow-up of 17.5 months (range, 0.5-69.6). Results: Among the 166 pts with R/R MCL, 153 (92%) received the pirtobrutinib approved dose of 200 mg/day, 152 (92%) had received prior cBTKi, of which 128 (84.2%) discontinued any prior cBTKi due to progressive disease (PD), and 15 (9.9%) due to toxicity. The cBTKi-pre-treated pts had a median age of 70 yrs (range, 46-88), 52% had intermediate-risk and 28.3% had high-risk sMIPI scores. The median number of prior lines of therapy was 3 (range 1-9), with most pts having received a prior anti-CD20 antibody (96.7%) and chemotherapy (90.1%). Additional prior therapies included hematopoietic stem cell transplantation (21.7%; 19.7% auto and 4.6% allo), BCL-2 inhibitor (15.8%), CAR-T cell therapy (8.6%). As of the data cutoff, 11 (7.2%) pts who received a prior cBTKi and 6 (42.9%) cBTKi naïve pts remained on treatment. The cBTKi pre-treated pts had an ORR of 49.3% (95% CI, 41.1-57.6), including 15.8% complete responses (CR) (n=24) and 33.6% partial responses (PR) (n=51). The 75 responding pretreated pts had a median DOR of 21.6 months (95% CI, 9.2-27.2) at a median follow-up of 24 months. The ORR among 128 pts who had discontinued any prior cBTKi due to PD and 15 pts who discontinued due to toxicity was 43.0% and 93.3%, respectively. The median PFS and OS for cBTKi pre-treated pts were 5.6 months (95% CI, 5.3-9.2) and 23.9 months (95% CI, 17.3-51.5), respectively. Fourteen pts (9.2%) were censored for PFS due to subsequent anticancer therapy without documented PD, including 8 pts who received CAR-T. The cBTKi naïve pts (n=14) had an ORR of 85.7% (95% CI, 57.2-98.2), including 50.0% CR (n=7) and 35.7% PR (n=5). The 12 responding naïve pts had a median DOR of 42.7 months (95% CI, 25.8-NE) at a median follow-up of 43 months. The median PFS and OS in the cBTKi naïve pts were 44.6 months (95% CI, 16.7-NE) and not reached (95% CI, 33.5-NE), respectively. Among all R/R MCL pts (n=166), the most frequent treatment-emergent adverse events (TEAE), regardless of attribution, were fatigue (31.9%), diarrhea (22.9%), anemia (18.1%), and dyspnea (18.1%). The most common Grade ≥3 TEAE was neutropenia/neutrophil count decreased (13.3%), and the rate of Grade ≥3 infections was 21.1%. Grade ≥3 hemorrhage/hematoma (2.4%) and all-grade atrial fibrillation/flutter (3.6%) were infrequent. In total, 13 (7.8%) pts had a fatal TEAE, with 4 (2.4%) classified as infections. Overall, 8 pts (4.8%) had treatment-related AE leading to dose reductions, and 6 (3.6%) had treatment-related AE leading to pirtobrutinib discontinuation. Conclusion: Pirtobrutinib continues to demonstrate efficacy in pts with heavily pre-treated R/R MCL including both those who previously received a cBTKi and those who were BTKi-naïve. The safety profile of pirtobrutinib remained favorable with a low-rate of dose reductions/discontinuations due to drug-related toxicity. No new safety signals were identified after up to 5 yrs of follow-up.
Prospera (ABNL-MARRO 002): A randomized phase 2 study of pacritinib vs. hydroxyurea in patients with advanced proliferative chronic myelomonocytic leukemia (CMML)
Mo, Qianxing, Buckley, Sarah , Sallman, David A. , Patnaik, Mrinal M. , Padron, Eric , Xie, Zhuoer , Lancet, Jeffrey E. , Savona, Michael R. , Komrokji, Rami S. , Wiseman, Daniel H.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3873-3873

10.1182/blood-2025-3873 Get It

Abstract Background and Significance: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic malignancy with overlapping dysplastic and proliferative features, a high risk of leukemic transformation, and no disease-modifying therapies. Patients with proliferative CMML often present with symptomatic monocytosis, leukocytosis, splenomegaly, and systemic inflammation, which contribute to shortened survival and impaired quality of life. Hydroxyurea (HU), the standard cytoreductive agent, provides transient control of leukocytosis but has no known disease modifying properties. In the phase 3 DACOTA trial (Itzykson et al., JCO 2022), decitabine modestly delayed leukemic transformation compared to HU but did not improve event-free or overall survival and was associated with increased early mortality. HU achieved a clinical benefit rate (CBR) of approximately 15% (excluding stable disease), highlighting the urgent need for safer and more effective therapies. Pacritinib is a potent and selective multikinase inhibitor with a kinome profile that targets key mediators of clonal proliferation and inflammatory signaling relevant to CMML. It inhibits JAK2 (IC₅₀ = 6 nM) and IRAK1 (IC₅₀ = 13.6 nM)—critical drivers of cytokine-mediated growth and monocytic skewing—while sparing JAK1, potentially reducing myelosuppressive toxicity. Pacritinib also inhibits CSF1R (IC₅₀= 39.5 nM) which is involved in monocytic differentiation. Preclinical models demonstrate that dual inhibition of JAK2 and IRAK1 suppresses CMML colony formation and prolongs survival in xenografts. Furthermore, CSF1R inhibition may reduce monocyte-lineage bias in leukemic clones. Clinically, pacritinib is FDA-approved for intermediate- or high-risk myelofibrosis with severe thrombocytopenia (platelets <50 × 10⁹/L) based on evidence of significant spleen volume and symptom reduction with limited hematologic toxicity. These mechanistic and clinical data provide a strong rationale for evaluating pacritinib in advanced proliferative CMML, a setting characterized by both cytokine-driven proliferation and treatment-limiting cytopenias. Study Design and Methods PROSPERA (NCT07033598) is a collaborative multicenter, open-label, randomized phase 2 trial. Sixty-six patients with WHO-defined CMML-1 or CMML-2 will be enrolled. Eligible patients must have proliferative features (WBC ≥13 × 10⁹/L) and advanced disease as defined by ≥5 cm palpable splenomegaly, symptom burden (Myeloproliferative Neoplasm-Symptom Assessment Form Total Symptom Score MPNSAF-TSS ≥20), or thrombocytopenia (platelets <100 × 10⁹/L). Prior JAK inhibitor therapy is not allowed. The trial will be conducted at approximately six sites across the United States and United Kingdom, with enrollment anticipated to begin by the end of 2025. Participants will be randomized 2:1 to receive either pacritinib (200 mg orally twice daily) or HU (dosed as per investigator discretion) for 48 weeks. Patients in the HU arm may cross over to pacritinib at Week 24 if, in the opinion of the treating physician, they are not deriving clinical benefit (after assessment of the primary endpoint). Randomization will be stratified by prior cytoreductive therapy (none vs. prior HU or hypomethylating agents). The primary endpoint is CBR at Week 24, defined by modified IWG MDS/MPN criteria incorporating hematologic improvement, spleen volume reduction, and symptom response. Secondary endpoints include CBR at any time, duration of response, event-free survival, leukemia-free survival, and overall survival. Correlative studies will assess treatment-related changes in clonal dynamics, cytokine signaling, and hematopoietic composition using longitudinal peripheral blood and bone marrow sampling. Single-cell transcriptomic and immunophenotypic profiling will be employed to characterize pacritinib's impact on both the malignant clone and the surrounding immune microenvironment.
Upstream integration of implementation planning in clinical trials through the blood and marrow transplant clinical trials network
DeSalvo, Anna M. , Ragon, Brittany Knick , Hamilton, Betty K. , Borogovac, Azra , Horowitz, Mary, Khera, Nandita , Keyzner, Alla , Efebera, Yvonne A. , Horwitz, Mitchell E. , Wall, Sarah, Stewart, Valerie , Heuer, Mykala, Bhatt, Neel S. , Juckett, Mark , Devine, Steven M. , Dandoy, Christopher E. , Plastaras, John Peter , Wall, Sarah , Heuer, Mykala, Molfenter, Todd

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 7913-7913

10.1182/blood-2025-7913 Get It

Abstract Background: Dissemination and implementation science (D+I) efforts often begin after clinical trial (CT) efficacy data are available. However, delaying this work limits opportunities to identify barriers and facilitators that can enhance adoption of evidence-based practices. Integrating D+I during trial development, activation, and conduct supports more timely, effective, and scalable implementation. The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) includes >125 centers, conducting transplant and cellular therapy (TCT) trials with practice-changing potential, with >17,000 patients enrolled since 2001. Data from Center for International Blood and Marrow Transplant Research (CIBMTR) provides a way to measure real-world adoption. With this comprehensive structure in place, the BMT CTN launched a D+I Committee that established a D+I process to better understand uptake of CT findings and to leverage that information to promote adoption. Methods: Informed by established D+I frameworks, a structured, cyclical process to integrate implementation considerations spanning the CT lifecycle was developed. A multidisciplinary team including experts in D+I, clinicians, and investigators iteratively refined the proposed D+I algorithm. The process begins upstream when a trial concept is approved to move forward, it is shared with the D+I Committee for initial assessment. This includes a landscape review for studies in development using CIBMTR data, literature, and expert experience. The Committee then reviews the developing protocol with the BMT CTN protocol team to proactively identify implementation barriers and facilitators to implementation in real-world settings and outline plans for dissemination. The Committee also provides recommendations for integrating relevant implementation data collection and analyses within the protocol. After study completion, both clinical efficacy and implementation outcomes are analyzed, followed by active dissemination. Additional assessment using surveys, qualitative methods, and CIBMTR data occurs after dissemination to understand adoption. Insights gathered also inform further refinement of the process. Tools and templates are in development to build capacity and ensure consistency for Committee members. Results: To date, the Committee has published three peer-reviewed articles addressing implementation implications of three BMT CTN trials (PMC7735536, PMC8578257, PMC9364468) and a fourth is in press. Using the designed D+I process flow, a current effort used a survey sent to US CIBMTR centers, to evaluate factors influencing the implementation of results of the BMT CTN 1703 trial of post-transplant cyclophosphamide as graft-versus-host disease (GvHD) prophylaxis and assessed dissemination and adoption considerations for the upcoming BMT CTN 2203 CT of ruxolitinib as GvHD prophylaxis. CIBMTR data is being analyzed to demonstrate practice patterns before, during, and after BMT CTN 1703 study completion. This effort has allowed for further refinement of the BMT CTN D+I process flow and has highlighted critical opportunities for incorporating dissemination and implementation objectives and endpoints into BMT CTN protocols. We also used the process to guide a review of severe aplastic anemia treatment gaps and ongoing studies. This review underscored how proactive transplant and non-transplant stakeholder engagement and early implementation planning, core elements of this process, can bridge evidence to practice and advance access to care. A complementary survey on current practice patterns in severe aplastic anemia is ongoing. Conclusions: With the existing structure of the BMT CTN and associated practice registry of the CIBMTR, the BMT CTN D+I Committee developed a systematic process to build D+I considerations into trial workflows to increase real-world impact. This process aims to ensure that barriers to uptake of trial results can be identified and addressed appropriately, improving care quality for patients undergoing TCT.
Retrieval-Augmented GPT-4 Improves NCCN-Concordant Lymphoma Treatment Recommendations
Yost, Connor , Monick, Sarah, Tripathi, Nikita , Palumbo, Peter, Kumar, Yash, Ertz-Archambault, Natalie , Galamaga, Robert , Yost, Connor , Loaiza‐Bonilla, Arturo , Palumbo, Peter, Leyfman, Yan , Kumar, Yash

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 7914-7914

10.1182/blood-2025-7914 Get It

Abstract While the use of NCCN guidelines is essential in lymphoma care, adherence among oncologists remains highly variable. Real-world concordance ranges from 65–80% overall, dropping to as low as 11–46% for certain lymphoma subtypes. Although 88% of clinicians report using NCCN guidelines for Hodgkin lymphoma, adherence to PET-adapted approaches is inconsistent. This gap highlights a critical need for tools that support guideline-concordant care.Large language models (LLMs) such as GPT–4 promise decision support, yet hallucinations and divergence from evidence-based care remain obstacles. We assessed whether retrieval-augmented generation (RAG) with National Comprehensive Cancer Network (NCCN) guidelines improves GPT–4 performance in lymphoma treatment recommendation tasks. To address this, we developed a RAG-enhanced GPT-4 agent (RAG-GPT) by indexing the 2025 NCCN Lymphoma Guidelines into a vector database. Fifty clinical vignettes spanning diverse lymphoma subtypes were compiled from published case reports; this sample provides 80 % power (α = 0.05) to detect a mean score difference of ≥ 0.18 on the modified Generative AI Performance Score (mG-PS). Guideline concordance was assessed based on NCCN guidelines and clinical judgment reflecting real-world oncological decision-making. Scores were normalized between -1.0 and 1.0 for consistent evaluation. Readability and rationale clarity were rated on a 5-point Likert scale. Baseline GPT-4 and RAG-GPT generated treatment plans via standardized prompts. An oncologist scored all outputs with mG-PS, which rates NCCN concordance (0.0–1.0) and penalizes hallucinations (-0.25 to –1.0). RAG-GPT achieved a higher mean mG-PS (0.32) than baseline GPT–4 (0.10) (t(98)=-2.11, p=0.038; mean score difference ΔmG-PS=0.22). Importantly, RAG-GPT eliminated severe hallucinations, reinforcing confidence in the safety of its treatment reccomendations. Fully concordant “gold-standard” plans were produced in 46 % of vignettes with RAG-GPT versus 22 % with baseline. Readability scores favored RAG-GPT modestly without statistical significance. Lymphoma's bimodal age distribution, heterogeneity, and lack of standardized treatment algorithms, coupled with regimen toxicity and the need to account for patient frailty and comorbidities, create complex clinical scenarios that constrain LLM applicability for nuanced decision-making. Non-Hodgkin lymphoma, particularly relapsed/refractory, transformed disease, or rare subtypes, lacks a defined standard of care, leading reviewers to rely on clinical judgment or published case series beyond NCCN guidelines. This underscores a key limitation of LLM-supported tools: their performance is highly dependent on the presence of clear algorithmic consensus within a given disease. Linking GPT-4 to NCCN guidelines via RAG significantly improved treatment accuracy and reduced hallucination severity in lymphoma, though performance remained lower than prior RAG studies in cancers like breast and CNS suggesting a greater impact on hallucination reduction than on retrieval of a consistent gold standard regimen. These findings support continued development and prospective validation of guideline-anchored LLMs for clinical use.
Outcomes of stem cell boost (SCB) versus supportive care alone for prolonged cytopenias after chimeric antigen receptor T cell therapy (CAR-T) in relapsed/refractory multiple myeloma (RRMM): A muli-center real-world analysis
Varga, Cindy , Robinson, Myra, Davis, James A. , Hashmi, Hamza , Martin, Thomas N., Kumar, Anupama, Sborov, Douglas W. , Shune, Leyla , Bhurtel, Jenny , Afrough, Aimaz , Dhakal, Binod , Forsberg, Peter A. , Purvey, Sneha , Khouri, Jack , Lin, Yi , Sidana, Surbhi , Midha, Shonali , Haider, Asad , Patel, Krina K. , Ferreri, Christopher J. , Sidana, Surbhi , Davis, James A , Robinson, Myra M , Martin, Thomas, Wagner, Charlotte B , Hansen, Doris K. , Puglianini, Omar Castañeda , Anderson, Larry D. , Dhakal, Binod , Herr, Megan M. , Richard, Shambavi , Lieberman-Cribbin, Alex , Sherbenou, Daniel W , Kocoglu, Mehmet H.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 1035-1035

10.1182/blood-2025-1035 Get It

Abstract Background: Prolonged cytopenias are a well-recognized complication following CAR-T therapy, leading to increased morbidity and healthcare utilization. Autologous SCB offers a potential strategy to promote hematologic recovery. We conducted a retrospective multi-institutional analysis across 18 centers comparing outcomes of SCB versus supportive care alone in RRMM patients who experienced prolonged cytopenias >30 days after CAR-T infusion. Methods: Patients were included if they received SCB within 1 year after commercial CAR-T between 6/2021 and 3/2024. To identify matched controls, we reviewed other CAR-T recipients from the same consortium and selected those with an absolute neutrophil count (ANC) of <0.72x109/L and platelet count of <21K at day 30 post-infusion-thresholds representing the 75th percentile of cytopenia severity in the SCB cohort. These criteria ensured control patients had comparable hematologic toxicity but without SCB. Hematologic recovery in the SCB cohort was assessed using the CIBMTR engraftment criteria. For the non-SCB (nSCB) group, cell counts were analyzed cross-sectionally at day 90 post-CAR-T and compared to the SCB cohort with Kruskal Wallis tests. Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan Meier methods. Results: Of the 590 CAR-T recipients, 91 patients (15.4%) developed prolonged cytopenias; 39 patients received SCB and 52 did not. SCB patients more frequently had ISS stage III disease (23.1% vs. 11.5%), exrtamedullary disease (59% vs. 46.2%) and penta-refractory status (43.6% vs. 34.6%). The median number of prior lines of therapy was 6 in both cohorts. Thirteen patients (33.3%) in the SCB and 11 (21.2%) in the nSCB received high intensity infusional chemotherapy (DCEP/PACE/HyperCVAD). Pre-CAR-T cytopenias tended to be less frequent in the SCB vs. nSCB cohort: ANC <1000 in 5.1% vs. 13.5%, Hgb <8 in 23.1% vs. 21.2%, and platelets <50K in 28.2% vs. 40.4%. Median plasmacytosis in the bone marrow prior to CAR-T in the SCB group was 35% and 47.5% in the nSCB group. In the SCB cohort, 2 patients harbored DNMT3A mutations, one of whom had CCUS. Ide-cel was administered in 64.8% and cilta-cel in 35.2% of all patients. The rates and grades of cytokine release syndrome did not differ between groups. Six patients (15.4%) had HLH in the SCB group vs. none in the control group. All (100%) SCB patients received growth factor support; 58% also received TPO agonists. In the nSCB group, 43 patients (82.7%) received growth factor, and 16 patients (30.8%) received TPO agonists. Out of 24 pre-SCB bone marrow biopsies available, only 1 patient had relapsed MM while the remainder had hypocellular marrows. Median CD34+ cell dose was 2.93 million/kg (range: 1.76-23.55) administered at a median of 53 days post-CAR-T (range 24-265). All but one patient (97.4%) in the SCB group achieved hematologic recovery; median time to recovery was 24 days (range 9-87). No new toxicities attributable to SCB were observed. On day 90 post CAR-T infusion, SCB patients had higher median ANC (2.12 vs. 1.59x109/L, p=0.277), Hgb (10.6 vs. 8.7g/dL, p=0.002), and platelet counts (135 vs. 35K/L (p<0.001). Minimal residual disease negativity was achieved in 82.4% (SCB) vs. 83.3% (nSCB). Infections occured in 53.8% and 48.1% of SCB and nSCB cohorts. All serious infections occurred prior to SCB. There were 12 deaths in the SCB group (7 from disease progression, 2 from infection, 1 from neurotoxicity (NT), and 1 unknown) and 27 in the nSCB group (22 from progression, 3 from infection, 1 from HLH, 1 from NT). After a median follow-up period of 12.6 months in the SCB cohort and 11.6 months in the nSCB arm, the mPFS was 11.0 months and 8.2 months, respectively. The mPFS was 10.6 months (SCB) and 5.8 months (nSCB) (p=0.216), and 11.0 months (SCB) and 10.9 months (nSCB), for ide-cel and cilta-cel treated-patients, respectively. Median OS was not reached vs.12.3 months in the SCB vs. nSCB groups, respectively. Conclusion: Overall, SCB was safe and effective in promoting rapid hematologic recovery in nearly all patients. Compared to controls, SCB recipeints had significantly higher Hgb and platelet levels by day 90 post-CAR-T infusion. SCB was associated wih a near doubling of PFS in patients who received ide-cel, though interpretation is limited by non-randomized design and small sample size. Further study is needed to optimize paient selection, timing, and integration of SCB into CAR-T care.
Robust HbF induction and improvement of anemia and hemolysis with base editing in sickle cell disease: Safety and efficacy findings from the ongoing BEACON study
Sharma, Akshay , Frangoul, Haydar , Mapara, Markus Y. , Dalal, Jignesh , Alavi, Asif, Jaroscak, Jennifer, Ayala, Ernesto , Ziga, Edward, Rifkin-Zenenberg, Stacey , Ambati, Srikanth, Chen, Yinzhong , Chesler, Sarah, Joseney-Antoine, Marcelyne, Ianniello, Leanne, Habtemariam, Bahru, Lin, Ling , Goyal, Sunita , Simon, Amy, Gupta, Ashish V , Kanter, Julie , DiPersio, John F. , Eapen, Mary , Chockalingam, Priya , Goyal, Sunita, Thompson, Alexis A. , Heeney, Matthew M.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2532-2532

10.1182/blood-2025-2532 Get It

Abstract Introduction Elevated levels of fetal hemoglobin (HbF) ameliorate sickle cell disease (SCD) manifestations. BEAM-101 is an investigational cell therapy comprising ex vivo base-edited autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) that directly target the HBG1/2 promoters to disrupt BCL11A binding, switching production from sickle (HbS) to majority anti-sickling HbF. We present ongoing data from the BEACON study (NCT05456880), a Phase 1/2, single-arm, open-label study evaluating a single dose of BEAM-101 in individuals with SCD and severe vaso-occlusive crises (sVOCs). Methods Eligible patients were aged 12–35 years with SCD and ≥4 sVOCs in the 2-year period prior to informed consent. After mobilization with weight-based or tiered fixed-dose plerixafor, autologous CD34+ HSPCs were collected by leukapheresis and genetically modified with an adenine base editor. Following conditioning with pharmacokinetically adjusted myeloablative busulfan (target cumulative AUC 80 hr*mg/L), patients received a single dose of BEAM-101 (≥3.0×106 viable CD34+ cells/kg). Patients were then monitored for neutrophil and platelet engraftment, adverse events (AEs), total Hb, Hb fractions, % F-cells, hemolysis markers, sVOCs, and additional protocol endpoints for up to 24 months. Results As of June 16, 2025, enrollment has been completed and 46 patients have initiated mobilization. Of the 26 patients who have received BEAM-101, mean duration of follow-up was 6.2 (range 1.0–18.7) months. Baseline demographics were: age 18–34 years, 24 βS/βS genotype, 21 self-reported Black/African American, and 11 female. One patient, who successfully engrafted and obtained stable HbF levels >60%, withdrew consent 5 months post-infusion. For the 26 treated patients, the median number of stem cell collection cycles was 1 (range 1–4); 18 (69.2%) required a single cycle, 4 required 2 cycles, and 4 required >2 cycles. Target cell dose was achieved with a median of 3 (1–12) collection days. Patients received a mean BEAM-101 dose of 8.4 (range 3.2–23.4) ×106 viable CD34+ cells/kg. By the data cut, patients achieved neutrophil (n=26) and platelet (n=24) engraftment at a median of 18 (12–30) days and 19 (11–50) days, respectively, with a median duration of 7 (4–17) days of neutropenia. Of the 24 evaluable patients, 9 (37.5%) achieved platelet engraftment without requiring platelet transfusion through the transplant process. No patients had ≥Grade 3 AEs or serious AEs related to BEAM-101. One patient died due to respiratory failure, assessed as likely related to busulfan conditioning, 4 months post-infusion as previously reported. Mean total Hb increased to 12.1 (range 9.0–14.7) g/dL by Month (M) 1 (n=24), 15.6 (11.9–18.6) g/dL by M6 (n=11), and was sustained through follow-up. Four patients had total Hb levels above the normal range beyond M6 without any associated clinical manifestations or need for therapeutic intervention. Erythropoietin levels trended towards normal in all patients, including those with elevated total Hb. Mean endogenous HbF (HbF/[HbF+HbS]) was >60% and HbS was <40% by M1, which was sustained through last follow-up. At M6, mean % F-cells were 99.2% (97.0–99.9; n=10) and mean HbF/F-cell was 20.8 (18.0–23.9; n=9) pg, exceeding the protective threshold of 10 pg against sickling. Peripheral blood editing was at a mean of 68.5% by M3 (n=16), 69.6% by M6 (n=10), and 72.8% by M12 (n=5). Hemolysis markers and sickling parameters normalized or improved for all patients. No patients experienced any investigator-reported sVOCs post-engraftment. Conclusions The BEAM-101 treatment process is characterized by a low number of mobilization and collection cycles and high editing efficiency, resulting in rapid neutrophil and platelet engraftment and robust pancellular HbF expression, with durability observed up to 18 months. Additionally, there is a corresponding reduction in HbS levels to <40%, and improvements or resolution of hemolysis parameters and anemia, along with resolution of investigator-reported sVOCs post-engraftment. The safety profile of the BEAM-101 treatment regimen is consistent with busulfan conditioning, autologous HSCT, and underlying SCD. These results demonstrate the potential for base editing of the HBG1/2 promoters as a safe and effective therapeutic modality for the treatment of SCD that also has the potential to minimize hospitalization and treatment process burden for patients, families, and sites.
Lymphovision: A lymphoma-specialized foundation model for histology-based lymphoma classification and subtyping
Seheult, Jansen N. , Han, Wenchao, Keser, Reyhan Kevser , Sapkota, Nishchal, Kumar, Nilesh, Mwangi, Raphael , Dalland, Joanna , Larson, D. J., Zhang, Chi , Dangott, Bryan, McClintock, David S. , Reed, Katelyn A. , Schwartz, Kaitlin, Bjorheim, Annette, Lee, Jodi, Halvorson, J. Derek, Nowakowski, Grzegorz S. , Ansell, Stephen M. , King, Rebecca, Seheult, Jansen N , Tavolara, Thomas Erol , Kumar, Nilesh, Larson, Daniel, Gibson, Sarah E. , Horna, Pedro , Schwartz, Kaitlin, Lee, Jodi, Halvorson, Joseph, Witzig, Thomas E. , Maurer, Matthew J. , Cerhan, James R. , Hsi, Eric D.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 117-117

10.1182/blood-2025-117 Get It

Abstract Background: Recent advances in computer vision have given rise to image foundation models (FMs), large-scale neural networks pre-trained on millions of unlabeled histopathology patches, which can learn generalizable representations of tissue morphology. In many cancers, these FMs have predicted genetic mutations and prognoses directly from histology, suggesting that morphology encodes “hidden” molecular information. In lymphoma, this field is nascent but growing.General-purpose histopathology FMs have limited representation of lymphoid morphology. We developed and evaluated LymphoVision, a lymphoma-specialized image foundation model pretrained with self-supervised learning, to extract clinically meaningful features from routine hematoxylin and eosin (H&E) histology. Methods: LymphoVision was pre-trained using knowledge distillation and consistency (DINOv2) on over 37 million multi-resolution patches (5x, 10x, 20x, 40x) sampled using a density-aware strategy from 31,211 H&E whole slide images (WSIs) from 9,155 archival lymphoma and reactive lymphoproliferative cases. To ensure diverse, representative samples, our patch sampling method uses an efficient graph-based clustering algorithm and prioritizes morphologically informative regions by clustering patch embeddings and performing density sampling within each cluster. The pretrained encoder was evaluated using a clustering-constrained attention multiple instance learning (MIL) framework on three diagnostic tasks: (1) cell-of-origin (COO) classification in diffuse large B-cell lymphoma (DLBCL), distinguishing germinal center B-cell (GCB) from non-GCB subtypes based on the Hans immunohistochemistry algorithm; (2) follicular lymphoma (FL) grading, differentiating low-grade (grades 1–2) from high-grade (grade 3); and (3) multiclass lymphoma subtype classification across six categories: DLBCL, FL, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), classical Hodgkin lymphoma (CHL), and benign/reactive lymphoid conditions. WSI-level labels were derived from pathology reports, and none of the evaluation cases were included in pretraining. Models used a ViT-Giant LymphoVision backbone to generate 20x patch embeddings, followed by MIL using 50% training data and 2-fold cross-validation (25% validation, 25% test). Performance was assessed using area under the receiver operating characteristic curve (AUC), accuracy, recall (sensitivity) and F1 score. Results: For DLBCL COO classification (total n=358 cases), LymphoVision achieved a mean test AUC of 0.93 (range 0.92–0.94), accuracy of 84.5% and F1 of 0.85 across two independent test folds (n=91 per fold, 50% GCB). These results outperformed general-purpose FMs on the same task and cases, including Virchow-v2 (AUC 0.85) and UNI-v2 (AUC 0.88), despite those models being pretrained on 10–100 times more images. For FL grading (total n=660 cases), the test set in each fold included 166 cases (18% grade 3), yielding a mean test AUC of 0.88 (range 0.87–0.90), accuracy of 89.2% and F1 of 0.80. In multiclass lymphoma subtype classification (total n=1,176 cases), the test set included 296 cases per fold. LymphoVision achieved a mean test AUC of 0.98 (range 0.97-0.99), mean test accuracy of 87.1% and mean F1 of 0.84. Class-wise recall was 92.0% for DLBCL (n=112), 88.2% for FL (n=72), 77.2% for MZL (n=29), 70.8% for MCL (n=35), 87.5% for CHL (n=24), and 95.8% for benign/reactive lymphoid conditions (n=24). Conclusion: LymphoVision is a lymphoma-specialized FM trained using self-supervision that achieves high diagnostic accuracy across multiple clinically meaningful tasks using weak supervision and standard H&E images, suggesting the encoder has learned fine-grained lymphoma morphology. Based on historical benchmarks from the 1997 International Lymphoma Study Group classification project, expert hematopathologists achieved diagnostic agreement rates of 55% to 84% using H&E morphology alone for the non-Hodgkin lymphoma (NHL) entities included in our multiclass task. LymphoVision approached or exceeded these benchmarks. These findings underscore the value of our approach using disease-specialized pretraining and intelligent patch sampling for data-efficient histopathology learning. LymphoVision has the potential to augment diagnostics, enable scalable AI-powered classification in real-world workflows, and serve as a foundation for prognostic and theragnostic applications. External validation and multimodal integration are ongoing.
Genomic and transcriptomic landscape of extranodal marginal zone lymphoma
Lossos, Izidore S., Biral, Leo, Thakkar, Devang, Naresh, Kikkeri N, Ondrejka, Sarah, Hsi, Eric, Xu, Mina, Koff, Jean, Jaye, David, Nørgaard, Peter, Breinholt, Marie Fredslund, Leeman-Neill, Rebecca, Shingleton, Jennifer, Happ, Lanie, Love, Cassandra, Mason, Emily F., Louissaint, Abner, Ong, Choon Kiat, Cheng, Chee Leong, Pillai, Raju, Pedersen, Mette, Yin, C. Cameron, Au-Yeung, Rex, Karjalainen-Lindsberg, Marja-Liisa, Chadburn, Amy, McKinney, Matthew, Sojitra, Payal, Evans, Andrew, Czader, Magdalena, Jiong, Yan, Dave, Sandeep, Chapman, Jennifer, Lossos, Izidore S., Biral, Leonardo P. A. , Thakkar, Devang, Naresh, Kikkeri N, Ondrejka, Sarah, Hsi, Eric, Xu, Mina, Koff, Jean, Jaye, David, Nørgaard, Peter, Breinholt, Marie Fredslund, Leeman-Neill, Rebecca, Shingleton, Jennifer, Happ, Lanie, Love, Cassandra, Mason, Emily F., Louissaint, Abner, Ong, Choon Kiat, Cheng, Chee Leong, Pillai, Raju, Pedersen, Mette, Yin, C. Cameron, Au-Yeung, Rex, Karjalainen-Lindsberg, Marja-Liisa, Chadburn, Amy, McKinney, Matthew, Sojitra, Payal, Evans, Andrew, Czader, Magdalena, Jiong, Yan, Dave, Sandeep, Chapman, Jennifer

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 1761-1761

10.1182/blood-2025-1761 Get It

Abstract Marginal zone lymphoma (MZL) is an uncommon non-Hodgkin B-cell lymphoma accounting for 7-10% of lymphoma diagnoses. Extranodal MZL (EMZL) of mucosa-associated lymphoid tissue (MALT) is the most common subtype (61%) of MZL. While the mutational landscape, chromosomal aberrations and transcriptome of nodal and splenic MZL have been extensively evaluated, the mutational landscape of EMZL has only been evaluated in a small number of patients and mainly by targeted sequencing. Consequently, the comprehensive genomic landscape of EMZL remains largely uncharacterized. Herein, we performed whole exome sequencing followed by targeted sequencing of potential tumor driver genes, copy number and/or RNA transcriptome analyses in 165 patients with pretreatment EMZL tumors involving 16 anatomic locations. All samples were collected and underwent expert review as part of the Atlas of Blood Cancer Genomes consortium. The most common anatomic locations were ocular adnexa (OAMZL) (n=35), gastric (n=25, including 6 positive for Helicobacter pylori), salivary glands (n=25), and lungs (n=24). Using common criteria for variant mutation calling and significant focal copy number (CN), we identified 1218 variants (1030 missense and 188 truncation mutations) across 174 genes and 2837 CN focal alterations (1614 copy gains and 1223 copy number losses). Of these genes, 44 and 11 were mutated in >5% and >10% of specimens, respectively. We detected variants identified previously by targeted sequencing in EMZL from different locations (e.g. TNFAIP3 (A20) (12%), TBL1XR1 (13%), SPEN (10%), CARD11 (7%), TET2 (7%) and CREBBP (6%)). We detected mutations in KLF2 (10 mutations in 8 EMZL patients) and PTPRD (7 mutations in 7 EMZL patients) that were previously suggested to be specific for splenic and nodal MZL, respectively. We also detected variants not previously reported in EMZL, including a transcriptional factor ZEB2, LRP1B,and others. The most frequently mutated gene in our study (25% of tumors) was IGLL5. Some mutations were limited to specific locations (e.g. ZEB2 mutations seen exclusively in gastric and salivary gland EMZL), while most were observed across all anatomic locations. There was no association between specific mutations and clonal IGHV, in contrast to previous reports. Using Enrichr tool, we observed enrichment of mutations in genes belonging to the B cell receptor activation, NOTCH signaling, Wnt-beta catenin signaling, NF-kB signaling , PI3K AKT signaling, DNA repair and other pathways. Chromosomal and copy number changes were also commonly observed including previously reported trisomy of chromosomes 3 and 18. Combining DNA mutations and CN alterations, the number of genetic lesions per tumor sample in the 174 mutated genes ranged from 0 to 95, with an average load of 17 lesions per case. RNA sequencing was successful in 159 EMZL tumors from 16 distinct anatomic locations. Unsupervised clustering using all genes with a median log2-normalized gene expression value greater than 5 and a standard deviation greater than 1 (1323 genes) demonstrated that the majority of gastric EMZL with and without H. pylori infections clustered together on 2 dendrograms as did most of the samples of OAMZL. Since the clustering could be forced by organ-specific and not tumor-specific gene expression, we next focused on the expression of the 345 genes from the LM22 matrix that passed our transcriptomic row filtering. Unsupervised clustering resulted in clustering of most gastric EMZL irrespective of H. pylori positivity together in the same dendrogram branch, accompanied by few additional EMZL from other anatomic locations. Most of the EMZL samples from other locations did not show preferential co-clustering together. On comparison of gene expression between gastric and OAMZL, there was enrichment of the B-cell receptor signaling pathway, B-cell activation, B-cell naïve and B-cell memory cells, B-cell proliferation and NF-kB signaling in the latter. Immune microenvironment analysis showed a statistically significant increase in resting mast cells and decrease in M1 macrophages in gastric EMZL and increase in regulatory T cells in salivary EMZL. The broad genomic studies reported here underscore the biological similarity of EMZL across anatomical sites with the potential exceptions of gastric EMZL (regardless of H. Pylori status). These data provide valuable genomic and transcriptomic resources to inform future diagnostic and therapeutic strategies.
CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel
McCauley, Ross, Zhang, Amy, Kota, Vamsi, Boccucci, Jacob, Grunwald, Michael, Ulrickson, Matthew, Hill, LaQuisa, Muhsen, Ibrahim, Sasine, Joshua, Advani, Anjali, Aldoss, Ibrahim, Sandhu, Karamjeet, Reshef, Ran, Luskin, Marlise, Lin, Chenyu, Cassaday, Ryan, Kopmar, Noam, Solh, Melhem, Bobillo, Silvina Odstrcil, Tsai, Stephanie, Hilal, Talal, Shah, Bijal, Faramand, Rawan, Park, Jae, Valtis, Yannis, Othman, Tamer, Vasu, Sumithira, Bezerra, Evandro, Leonard, Jessica, Tan, Virginia, O'Dwyer, Kristen, Moore, Jozal, Jamy, Omer, Mohty, Razan, Kumaran, Muthu, Hoeg, Rasmus, Stock, Wendy, Oliai, Caspian, Lill, Georgia, Schwartz, Marc, Koura, Divya, Dykes, Kaitlyn, Logan, Aaron, Daunov, Michael, Byrd, Ken, Yalniz, Fevzi, Frey, Noelle, Connor, Matthew, Yaghmour, George, Gatell, Vivian Irizarry, Jackson, Clayton, Oluwole, Olalekan, Al-Darobi, Ali, Chen, Evan, Lee, Catherine, O'Connor, Timothy, Dholaria, Bhagirathbhai, Bachanova, Veronika, Tracy, Sean, Srinagesh, Hrishikesh, Miller, Katharine, Sutherland, Katherine, Majhail, Navneet, Mountjoy, Luke, Malik, Shahbaz, Ramakrishnan, Aravind, Shaughnessy, Paul, Mathews, John, Wang, Eunice, Battiwalla, Minoo, Roloff, Gregory, Muffly, Lori, Muffly, Lori , Muffly, Lori , McCauley, Ross, Zhang, Amy, Kota, Vamsi, Boccucci, Jacob, Grunwald, Michael, Ulrickson, Matthew, Hill, LaQuisa, Muhsen, Ibrahim, Sasine, Joshua, Advani, Anjali, Aldoss, Ibrahim, Sandhu, Karamjeet, Reshef, Ran, Luskin, Marlise, Lin, Chenyu, Cassaday, Ryan, Kopmar, Noam, Solh, Melhem, Bobillo, Silvina Odstrcil, Tsai, Stephanie, Hilal, Talal, Shah, Bijal, Faramand, Rawan, Park, Jae, Valtis, Yannis, Othman, Tamer, Vasu, Sumithira, Bezerra, Evandro, Leonard, Jessica, Tan, Virginia, O'Dwyer, Kristen, Moore, Jozal, Jamy, Omer, Mohty, Razan , Kumaran, Muthu, Hoeg, Rasmus, Stock, Wendy, Oliai, Caspian, Lill, Georgia, Schwartz, Marc, Koura, Divya, Dykes, Kaitlyn, Logan, Aaron, Daunov, Michael, Byrd, Ken, Yalniz, Fevzi, Frey, Noelle, Connor, Matthew, Yaghmour, George, Gatell, Vivian Irizarry, Jackson, Clayton, Oluwole, Olalekan, Al-Darobi, Ali, Chen, Evan, Lee, Catherine, O'Connor, Timothy, Dholaria, Bhagirathbhai, Bachanova, Veronika, Tracy, Sean, Srinagesh, Hrishikesh, Miller, Katharine, Sutherland, Katherine, Majhail, Navneet, Mountjoy, Luke, Malik, Shahbaz, Ramakrishnan, Aravind, Shaughnessy, Paul, Mathews, John, Wang, Eunice, Battiwalla, Minoo, Roloff, Gregory

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2396-2396

10.1182/blood-2025-2396 Get It

Abstract Introduction: CD19-directed CAR T-cell (CAR-T) therapy has substantially improved clinical outcomes for adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). However, notable toxicities are associated with CAR-T, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Variable practice patterns have emerged regarding the use of CRS/ICANS prophylaxis (ppx) via corticosteroids and/or other pharmacologic agents, but the utility of these approaches on reducing CRS or ICANS following CAR-T in B-ALL remains unknown. Thus, we utilized the Real-World Outcomes Collaborative for CAR T in ALL (ROCCA) database to evaluate associations between ppx and the development and severity of CRS or ICANS following brexucabtagene autoleucel (brexu-cel) for B-ALL. Methods: Adult patients (pts) who received standard-of-care brexu-cel for relapsed/refractory B-ALL across 40+ US centers were included. Primary endpoints were the incidence of CRS and ICANS within 28 days of CAR-T infusion. Secondary endpoints included timing of CRS and ICANS onset, progression-free survival (PFS) and overall survival (OS). Univariable and multivariable logistic regression evaluated associations between ppx and incidence of CRS/ICANS; KM and log-rank methods were used for survival analyses. Results: A total of 378 pts were included: 53 pts (14.0%) received CRS/ICANS ppx and 325 (86.0%) received no ppx. Ppx agents included steroids only (26.4%), steroid and anakinra (52.8%), anakinra only (15.1%), and steroid and tocilizumab (5.7%). Pts in the ppx group had a higher proportion of Hispanic pts (64% vs 34%), Ph-like (36% vs 19%) and a lower proportion had 0-5% bone marrow blasts at apheresis (38% vs 53%). The ppx and no ppx groups were similar in age, prior therapies, CAR-T indication, and marrow blasts >50%. Cumulative incidence of any grade (gr) CRS was 94% with ppx and 86% with no ppx (p=0.025), of any gr ICANS was 53% with ppx and 51% with no ppx (0= 0.85). Cumulative incidence of gr 3-4 CRS was 9% in the ppx group and 10% in the no ppx group (p=1.00), of gr 3-4 ICANS was 26% in the ppx group and 29% in the no ppx group (p=0.71). Median time to onset for any gr CRS or any gr ICANS was identical in the ppx and no ppx cohorts (CRS: 5 days, range ppx 1-9 days, no ppx 0-14 days; ICANS: 7 days, ppx 1-20 days, no ppx 0-16 days). Univariate logistic regression analyses showed no significant association between ppx and the incidence of gr 2-4 CRS (OR 1.34, 95% CI: 0.75-2.40, p=0.326) or gr 3-4 ICANS (OR 0.88, 95% CI: 0.46-1.70, p=0.708). Multivariate analysis adjusting for ethnicity, leukemia genetic sub-type, and pre-apheresis disease burden similarly found no significant associations between ppx and gr 2-4 CRS (adjusted OR 1.06, 95% CI: 0.55-2.01, p=0.870) or gr 3-4 ICANS (OR 1.23, 95% CI: 0.59-2.55, p=0.584). When comparing steroid-only ppx (N=14) to steroid combinations or other drug ppx (N=39), there was no significant differences in gr 2-4 CRS (57% vs 44%, p=0.345) or gr 3-4 ICANS (43% vs 21%, p=0.115). Comparing cumulative incidence of dexamethasone (dex) exposure, pts in the ppx group had numerically greater dex exposure than pts in the no ppx group, with median (range) dosing of 182 mg (10-1386mg) and 100mg (1-4000mg), respectively. Finally, we found no significant differences in PFS or OS based on ppx. Median PFS was 9.6 months in the ppx group vs 13.3 months in the no ppx group (p=0.646) and median OS was 17.2 months in the ppx group vs 34.4 months in the no ppx group (p=0.170). Conclusions: In this large cohort of adult patients with R/R ALL receiving brexu-cel CAR-T therapy, prophylaxis intended to prevent CRS/ICANS was ineffective at reducing CRS/ICANS incidence, time to onset, or overall steroid exposure. Furthermore, PFS and OS were comparable between patients who received prophylaxis and those who did not. In the absence of prospective trials in B-ALL, these data suggest that current strategies of CRS/ICANS prophylaxis has limited benefit.